Company
Ascendis Pharma
Nasdaq: ASND
Hellerup, Denmark biopharmaceutical company that already markets two other TransCon endocrinology products, SKYTROFA and YORVIPATH, alongside Yuviwel for achondroplasia.
2 stories
Regulatory News has published 2 stories about Ascendis Pharma between 17 October 2026 and 29 October 2026, each sourced to the primary record — the regulator’s decision, the company’s filing or its own announcement. This page is generated from that coverage. Last updated 29 October 2026.
This page is generated from Regulatory News’ editorial coverage of Ascendis Pharma. It is not an advertisement.
On the record
- Company
- Ascendis Pharma A/S (Nasdaq: ASND)
- Headquarters
- Hellerup, Denmark
- Founded
- 2006, by President & CEO Jan Mikkelsen
- Regulator
- European Medicines Agency (CHMP)
Each line is taken from the most recent story of ours that states it.
